Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC.<br /><br /><br /><br />...
Author: Annual-Meeting
Added: 06/06/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Study | Texas University | Yervoy